8d6d - Revision history

OCA at 17:25, 18 October 2023

OCA — Wed, 18 Oct 2023 17:25:22 GMT

←Older revision		Revision as of 17:25, 18 October 2023
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[8d6d]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8D6D OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8D6D FirstGlance]. <br>		<table><tr><td colspan='2'>[[8d6d]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8D6D OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8D6D FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=QGY:(1P)-2-amino-5-bromo-1-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide'>QGY</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.35Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=QGY:(1P)-2-amino-5-bromo-1-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide'>QGY</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8d6d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8d6d OCA], [https://pdbe.org/8d6d PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8d6d RCSB], [https://www.ebi.ac.uk/pdbsum/8d6d PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8d6d ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8d6d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8d6d OCA], [https://pdbe.org/8d6d PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8d6d RCSB], [https://www.ebi.ac.uk/pdbsum/8d6d PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8d6d ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
-	[[https://www.uniprot.org/uniprot/PMYT1_HUMAN PMYT1_HUMAN]] Acts as a negative regulator of entry into mitosis (G2 to M transition) by phosphorylation of the CDK1 kinase specifically when CDK1 is complexed to cyclins. Mediates phosphorylation of CDK1 predominantly on 'Thr-14'. Also involved in Golgi fragmentation. May be involved in phosphorylation of CDK1 on 'Tyr-15' to a lesser degree, however tyrosine kinase activity is unclear and may be indirect. May be a downstream target of Notch signaling pathway during eye development.<ref>PMID:9001210</ref> <ref>PMID:10373560</ref>	+	[https://www.uniprot.org/uniprot/PMYT1_HUMAN PMYT1_HUMAN] Acts as a negative regulator of entry into mitosis (G2 to M transition) by phosphorylation of the CDK1 kinase specifically when CDK1 is complexed to cyclins. Mediates phosphorylation of CDK1 predominantly on 'Thr-14'. Also involved in Golgi fragmentation. May be involved in phosphorylation of CDK1 on 'Tyr-15' to a lesser degree, however tyrosine kinase activity is unclear and may be indirect. May be a downstream target of Notch signaling pathway during eye development.<ref>PMID:9001210</ref> <ref>PMID:10373560</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==

OCA at 04:20, 8 September 2022

OCA — Thu, 08 Sep 2022 04:20:25 GMT

←Older revision		Revision as of 04:20, 8 September 2022
Line 1:		Line 1:

	==Crystal Structure of Human Myt1 Kinase domain Bounded with compound 39==		==Crystal Structure of Human Myt1 Kinase domain Bounded with compound 39==
-	<StructureSection load='8d6d' size='340' side='right'caption='[[8d6d]]' scene=''>	+	<StructureSection load='8d6d' size='340' side='right'caption='[[8d6d]], [[Resolution\|resolution]] 2.35Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8D6D OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8D6D FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[8d6d]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8D6D OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8D6D FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8d6d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8d6d OCA], [https://pdbe.org/8d6d PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8d6d RCSB], [https://www.ebi.ac.uk/pdbsum/8d6d PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8d6d ProSAT]</span></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=QGY:(1P)-2-amino-5-bromo-1-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide'>QGY</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8d6d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8d6d OCA], [https://pdbe.org/8d6d PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8d6d RCSB], [https://www.ebi.ac.uk/pdbsum/8d6d PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8d6d ProSAT]</span></td></tr>
	</table>		</table>
		+	== Function ==
		+	[[https://www.uniprot.org/uniprot/PMYT1_HUMAN PMYT1_HUMAN]] Acts as a negative regulator of entry into mitosis (G2 to M transition) by phosphorylation of the CDK1 kinase specifically when CDK1 is complexed to cyclins. Mediates phosphorylation of CDK1 predominantly on 'Thr-14'. Also involved in Golgi fragmentation. May be involved in phosphorylation of CDK1 on 'Tyr-15' to a lesser degree, however tyrosine kinase activity is unclear and may be indirect. May be a downstream target of Notch signaling pathway during eye development.<ref>PMID:9001210</ref> <ref>PMID:10373560</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	PKMYT1 is a regulator of CDK1 phosphorylation and is a compelling therapeutic target for the treatment of certain types of DNA damage response cancers due to its established synthetic lethal relationship with CCNE1 amplification. To date, no selective inhibitors have been reported for this kinase that would allow for investigation of the pharmacological role of PKMYT1. To address this need compound 1 was identified as a weak PKMYT1 inhibitor. Introduction of a dimethylphenol increased potency on PKMYT1. These dimethylphenol analogs were found to exist as atropisomers that could be separated and profiled as single enantiomers. Structure-based drug design enabled optimization of cell-based potency. Parallel optimization of ADME properties led to the identification of potent and selective inhibitors of PKMYT1. RP-6306 inhibits CCNE1-amplified tumor cell growth in several preclinical xenograft models. The first-in-class clinical candidate RP-6306 is currently being evaluated in Phase 1 clinical trials for treatment of various solid tumors.
		+
		+	Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.,Szychowski J, Papp R, Dietrich E, Liu B, Vallee F, Leclaire ME, Fourtounis J, Martino G, Perryman AL, Pau V, Yin SY, Mader P, Roulston A, Truchon JF, Marshall CG, Diallo M, Duffy NM, Stocco R, Godbout C, Bonneau-Fortin A, Kryczka R, Bhaskaran V, Mao D, Orlicky S, Beaulieu P, Turcotte P, Kurinov I, Sicheri F, Mamane Y, Gallant M, Black WC J Med Chem. 2022 Jul 26. doi: 10.1021/acs.jmedchem.2c00552. PMID:35880755<ref>PMID:35880755</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 8d6d" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
	[[Category: Mader P]]		[[Category: Mader P]]

OCA at 11:14, 31 August 2022

OCA — Wed, 31 Aug 2022 11:14:39 GMT

←Older revision		Revision as of 11:14, 31 August 2022
Line 1:		Line 1:

	==Crystal Structure of Human Myt1 Kinase domain Bounded with compound 39==		==Crystal Structure of Human Myt1 Kinase domain Bounded with compound 39==
-	<StructureSection load='8d6d' size='340' side='right'caption='[[8d6d]]~~, [[Resolution\|resolution]] 2.35Å~~' scene=''>	+	<StructureSection load='8d6d' size='340' side='right'caption='[[8d6d]]' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>~~[[8d6d]] is a 2 chain structure.~~ Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8D6D OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8D6D FirstGlance]. <br>	+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8D6D OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8D6D FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=QGY:(1P)-2-amino-5-bromo-1-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide'>QGY</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8d6d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8d6d OCA], [https://pdbe.org/8d6d PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8d6d RCSB], [https://www.ebi.ac.uk/pdbsum/8d6d PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8d6d ProSAT]</span></td></tr>
-	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[https://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [https://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] </span></td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8d6d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8d6d OCA], [https://pdbe.org/8d6d PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8d6d RCSB], [https://www.ebi.ac.uk/pdbsum/8d6d PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8d6d ProSAT]</span></td></tr>	+
	</table>		</table>
-	== Function ==
-	[[https://www.uniprot.org/uniprot/PMYT1_HUMAN PMYT1_HUMAN]] Acts as a negative regulator of entry into mitosis (G2 to M transition) by phosphorylation of the CDK1 kinase specifically when CDK1 is complexed to cyclins. Mediates phosphorylation of CDK1 predominantly on 'Thr-14'. Also involved in Golgi fragmentation. May be involved in phosphorylation of CDK1 on 'Tyr-15' to a lesser degree, however tyrosine kinase activity is unclear and may be indirect. May be a downstream target of Notch signaling pathway during eye development.<ref>PMID:9001210</ref> <ref>PMID:10373560</ref>
-	<div style="background-color:#fffaf0;">
-	== Publication Abstract from PubMed ==
-	PKMYT1 is a regulator of CDK1 phosphorylation and is a compelling therapeutic target for the treatment of certain types of DNA damage response cancers due to its established synthetic lethal relationship with CCNE1 amplification. To date, no selective inhibitors have been reported for this kinase that would allow for investigation of the pharmacological role of PKMYT1. To address this need compound 1 was identified as a weak PKMYT1 inhibitor. Introduction of a dimethylphenol increased potency on PKMYT1. These dimethylphenol analogs were found to exist as atropisomers that could be separated and profiled as single enantiomers. Structure-based drug design enabled optimization of cell-based potency. Parallel optimization of ADME properties led to the identification of potent and selective inhibitors of PKMYT1. RP-6306 inhibits CCNE1-amplified tumor cell growth in several preclinical xenograft models. The first-in-class clinical candidate RP-6306 is currently being evaluated in Phase 1 clinical trials for treatment of various solid tumors.
-
-	Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.,Szychowski J, Papp R, Dietrich E, Liu B, Vallee F, Leclaire ME, Fourtounis J, Martino G, Perryman AL, Pau V, Yin SY, Mader P, Roulston A, Truchon JF, Marshall CG, Diallo M, Duffy NM, Stocco R, Godbout C, Bonneau-Fortin A, Kryczka R, Bhaskaran V, Mao D, Orlicky S, Beaulieu P, Turcotte P, Kurinov I, Sicheri F, Mamane Y, Gallant M, Black WC J Med Chem. 2022 Jul 26. doi: 10.1021/acs.jmedchem.2c00552. PMID:35880755<ref>PMID:35880755</ref>
-
-	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	</div>
-	<div class="pdbe-citations 8d6d" style="background-color:#fffaf0;"></div>
-	== References ==
-	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	~~[[Category: Non-specific serine/threonine protein kinase]]~~	+	[[Category: Mader P]]
-	[[Category: Mader, P]]	+	[[Category: Mao DYL]]
-	[[Category: Mao~~, D Y.L~~]]	+	[[Category: Orlicky S]]
-	[[Category: Orlicky, S]]	+	[[Category: Pau VPT]]
-	[[Category: Pau~~, V P.T~~]]	+	[[Category: Sicheri F]]
-	[[Category: Sicheri, F]]	+
-	~~[[Category: Kinase inhibitor complex]]~~	+
-	~~[[Category: Signaling protein]]~~	+
-	~~[[Category: Transferase-inhibitor complex~~]]	+

OCA at 05:15, 10 August 2022

OCA — Wed, 10 Aug 2022 05:15:33 GMT

←Older revision		Revision as of 05:15, 10 August 2022
Line 1:		Line 1:

	==Crystal Structure of Human Myt1 Kinase domain Bounded with compound 39==		==Crystal Structure of Human Myt1 Kinase domain Bounded with compound 39==
-	<StructureSection load='8d6d' size='340' side='right'caption='[[8d6d]]' scene=''>	+	<StructureSection load='8d6d' size='340' side='right'caption='[[8d6d]], [[Resolution\|resolution]] 2.35Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8D6D OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8D6D FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[8d6d]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8D6D OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8D6D FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8d6d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8d6d OCA], [https://pdbe.org/8d6d PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8d6d RCSB], [https://www.ebi.ac.uk/pdbsum/8d6d PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8d6d ProSAT]</span></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=QGY:(1P)-2-amino-5-bromo-1-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide'>QGY</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
		+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[https://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [https://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] </span></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8d6d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8d6d OCA], [https://pdbe.org/8d6d PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8d6d RCSB], [https://www.ebi.ac.uk/pdbsum/8d6d PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8d6d ProSAT]</span></td></tr>
	</table>		</table>
		+	== Function ==
		+	[[https://www.uniprot.org/uniprot/PMYT1_HUMAN PMYT1_HUMAN]] Acts as a negative regulator of entry into mitosis (G2 to M transition) by phosphorylation of the CDK1 kinase specifically when CDK1 is complexed to cyclins. Mediates phosphorylation of CDK1 predominantly on 'Thr-14'. Also involved in Golgi fragmentation. May be involved in phosphorylation of CDK1 on 'Tyr-15' to a lesser degree, however tyrosine kinase activity is unclear and may be indirect. May be a downstream target of Notch signaling pathway during eye development.<ref>PMID:9001210</ref> <ref>PMID:10373560</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	PKMYT1 is a regulator of CDK1 phosphorylation and is a compelling therapeutic target for the treatment of certain types of DNA damage response cancers due to its established synthetic lethal relationship with CCNE1 amplification. To date, no selective inhibitors have been reported for this kinase that would allow for investigation of the pharmacological role of PKMYT1. To address this need compound 1 was identified as a weak PKMYT1 inhibitor. Introduction of a dimethylphenol increased potency on PKMYT1. These dimethylphenol analogs were found to exist as atropisomers that could be separated and profiled as single enantiomers. Structure-based drug design enabled optimization of cell-based potency. Parallel optimization of ADME properties led to the identification of potent and selective inhibitors of PKMYT1. RP-6306 inhibits CCNE1-amplified tumor cell growth in several preclinical xenograft models. The first-in-class clinical candidate RP-6306 is currently being evaluated in Phase 1 clinical trials for treatment of various solid tumors.
		+
		+	Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.,Szychowski J, Papp R, Dietrich E, Liu B, Vallee F, Leclaire ME, Fourtounis J, Martino G, Perryman AL, Pau V, Yin SY, Mader P, Roulston A, Truchon JF, Marshall CG, Diallo M, Duffy NM, Stocco R, Godbout C, Bonneau-Fortin A, Kryczka R, Bhaskaran V, Mao D, Orlicky S, Beaulieu P, Turcotte P, Kurinov I, Sicheri F, Mamane Y, Gallant M, Black WC J Med Chem. 2022 Jul 26. doi: 10.1021/acs.jmedchem.2c00552. PMID:35880755<ref>PMID:35880755</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 8d6d" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Mader P]]	+	[[Category: Non-specific serine/threonine protein kinase]]
-	[[Category: Mao ~~DYL~~]]	+	[[Category: Mader, P]]
-	[[Category: Orlicky S]]	+	[[Category: Mao, D Y.L]]
-	[[Category: Pau ~~VPT~~]]	+	[[Category: Orlicky, S]]
-	[[Category: Sicheri F]]	+	[[Category: Pau, V P.T]]
		+	[[Category: Sicheri, F]]
		+	[[Category: Kinase inhibitor complex]]
		+	[[Category: Signaling protein]]
		+	[[Category: Transferase-inhibitor complex]]

OCA at 18:07, 27 July 2022

OCA — Wed, 27 Jul 2022 18:07:30 GMT

←Older revision		Revision as of 18:07, 27 July 2022
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 8d6d ~~is ON HOLD until Paper Publication~~	+	==Crystal Structure of Human Myt1 Kinase domain Bounded with compound 39==
-		+	<StructureSection load='8d6d' size='340' side='right'caption='[[8d6d]]' scene=''>
-	~~Authors~~: ~~Pau, V~~.P.T., ~~Mao, D~~.Y.L., ~~Mader~~, P., ~~Orlicky, S~~., ~~Sicheri, F~~.	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8D6D OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8D6D FirstGlance]. <br>
-	~~Description: Crystal Structure of Human Myt1 Kinase domain Bounded with compound 39~~	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8d6d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8d6d OCA], [https://pdbe.org/8d6d PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8d6d RCSB], [https://www.ebi.ac.uk/pdbsum/8d6d PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8d6d ProSAT]</span></td></tr>
-	[[Category: ~~Unreleased~~ Structures]]	+	</table>
-	[[Category: ~~Mao, D.Y.L~~]]	+	__TOC__
-	[[Category: ~~Orlicky, S~~]]	+	</StructureSection>
-	[[Category: ~~Pau, V.P.T~~]]	+	[[Category: Large Structures]]
-	[[Category: ~~Sicheri, F~~]]	+	[[Category: Mader P]]
-	[[Category: ~~Mader, P~~]]	+	[[Category: Mao DYL]]
		+	[[Category: Orlicky S]]
		+	[[Category: Pau VPT]]
		+	[[Category: Sicheri F]]

OCA at 07:26, 22 June 2022

OCA — Wed, 22 Jun 2022 07:26:12 GMT

←Older revision		Revision as of 07:26, 22 June 2022
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 8d6d is ON HOLD	+	The entry 8d6d is ON HOLD until Paper Publication

	Authors: Pau, V.P.T., Mao, D.Y.L., Mader, P., Orlicky, S., Sicheri, F.		Authors: Pau, V.P.T., Mao, D.Y.L., Mader, P., Orlicky, S., Sicheri, F.

-	Description: Crystal Structure of Human Myt1 Kinase domain Bounded with ~~RP1905~~	+	Description: Crystal Structure of Human Myt1 Kinase domain Bounded with compound 39
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
-	[[Category: Sicheri, F]]
	[[Category: Mao, D.Y.L]]		[[Category: Mao, D.Y.L]]
	[[Category: Orlicky, S]]		[[Category: Orlicky, S]]
-	[[Category: Mader, P]]
	[[Category: Pau, V.P.T]]		[[Category: Pau, V.P.T]]
		+	[[Category: Sicheri, F]]
		+	[[Category: Mader, P]]

OCA: Protected "8d6d" [edit=sysop:move=sysop]

OCA — Wed, 15 Jun 2022 04:12:19 GMT

Protected "8d6d" [edit=sysop:move=sysop]

←Older revision

Revision as of 04:12, 15 June 2022

OCA: New page: '''Unreleased structure''' The entry 8d6d is ON HOLD Authors: Pau, V.P.T., Mao, D.Y.L., Mader, P., Orlicky, S., Sicheri, F. Description: Crystal Structure of Human Myt1 Kinase domain B...

OCA — Wed, 15 Jun 2022 04:12:18 GMT

New page: '''Unreleased structure''' The entry 8d6d is ON HOLD Authors: Pau, V.P.T., Mao, D.Y.L., Mader, P., Orlicky, S., Sicheri, F. Description: Crystal Structure of Human Myt1 Kinase domain B...

New page

'''Unreleased structure'''

The entry 8d6d is ON HOLD

Authors: Pau, V.P.T., Mao, D.Y.L., Mader, P., Orlicky, S., Sicheri, F.

Description: Crystal Structure of Human Myt1 Kinase domain Bounded with RP1905
[[Category: Unreleased Structures]]
[[Category: Sicheri, F]]
[[Category: Mao, D.Y.L]]
[[Category: Orlicky, S]]
[[Category: Mader, P]]
[[Category: Pau, V.P.T]]